

FOR IMMEDIATE RELEASE

Contact:

Colleen Hittle

President & CEO

9001 Wesleyan Road Suite, 200

Indianapolis, IN 46268

Ph. (317) 569-9500 x 102

Fax (317) 569-9520

Cell (317) 201-8711

www.ansongroup.com

chittle@ansongroup.com

Anson Group provides broad regulatory support to assist start-up specialty pharmaceutical company achieve its first-ever drug approval by FDA

(Indianapolis, IN) January 18, 2011 – The Anson Group is pleased to announce today that its client ParaPRO has achieved the first-ever FDA approval for the Carmel, Indiana-based start-up specialty pharmaceutical company. ParaPRO achieved this approval for its innovative new treatment for head lice, Natroba™ (spinosad). Dr. Reed Tarwater, PhD, RAC, FRAPS, led the Anson team that guided the Natroba's drug development project from early planning through the IND and NDA filings, providing ParaPRO with a wide range of drug development services including project management, clinical study design and planning, case report form (CRF) review, investigational site management and monitoring, and data summary and presentation. In addition, Dr. Tarwater served as ParaPRO's liaison with FDA for regulatory issues management and represented them at multiple meetings with the Agency, leading to this successful drug approval.

ParaPRO licensed the worldwide marketing rights to spinosad for the treatment of head lice from Eli Lilly and Company in 2002. Spinosad, an insecticide derived from naturally occurring soil dwelling bacteria, has been used for control of predatory insects on plants and as an ingestible flea treatment for pets.

"The changing landscape of the pharmaceutical industry necessitates smaller, innovative companies be able to successfully commercialize products that represent unmet medical needs in markets that are not sufficiently large enough for major drug companies to pursue. The regulatory requirement for achieving new drug approvals are difficult and time consuming, and requires knowledgeable expertise across a number of disciplines in order to complete the process. The Anson Group is very proud of our ability to support necessary and emerging innovation to reach the market by providing world class regulatory affairs personnel that understand the expectations of the FDA, and we are pleased we can serve as a "virtual" regulatory affairs organization for an innovative client like ParaPRO" said Colleen Hittle, Managing Partner of the Anson Group.

"We could not have achieved this success without the assistance of the experts at The Anson Group" stated Bill Culpepper, III, President, ParaPRO LLC. "As a small startup company, it would have been very impractical to attempt to staff the wide range of clinical, toxicological, and regulatory expertise provided by The Anson Group and required to see

this project through”.

About Anson Group Headquartered in Carmel, Indiana, Anson Group is a minority- owned independent regulatory consulting organization with over 14 years experience as a leading provider of services and strategies for FDA product approval and compliance for devices, drugs, biologics, and combination products. Anson Group’s team of experienced industry experts tailors both enterprise strategies and clearly defined action plans that help its clients address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.

About spinosad Spinosad is a non-synthetic, fermentation product of the soil bacterium *Saccharopolyspora spinosa*. The spinosad mode of action in insects is to alter the function of nicotinic and GABA-gated ion channels to cause neuronal excitation of the insect nervous system. Spinosad was first identified in a soil sample taken in 1983 at an abandoned rum still on an island in the Caribbean. Spinosad’s insecticidal activity was first discovered in mosquito larvae in 1985, and its first commercial launch as an EPA- registered product was in 1997 for use against caterpillars in cotton. Due to its low toxicity to mammals, spinosad was able to attain its first commercial launch as an animal health product in 2000.

About ParaPRO ParaPRO is a specialty pharmaceutical company founded in 2002 to acquire, develop, and commercialize proprietary products in focused high potential markets. ParaPRO is a wholly owned subsidiary of SePRO Corporation, a management- owned life-sciences business started in 1994 by Bill Culpepper, a former employee of Eli Lilly and Company and Dow AgroSciences. SePRO Corporation provides the highest level of technical service to customers in specialty niche markets.